With advancements in technologies that capture circulating tumor cells, we propose that quantifying expression of HNRNPL and its circular RNA derivatives may be an effective biomarker of recurrence in TNBC patients given radiotherapy. This evidence concerns the gene HNRNPL and neoplasm.